Journal of Bioscience and Bioengineering vol.112 cover

The Journal of Bioscience and Bioengineering (JBB) is an international journal devoted to the rapid publication of papers describing original research in the field of biotechnology. JBB encourages and publishes new concepts in technology/methodology that significantly advance the understanding of bioscience and bioengineering and contribute to the development of chemical, pharmaceutical, medical, food, and agricultural industries. The Editorial Committee makes its best efforts to provide expeditious, rigorous and fair peer-review, ensuring the high quality of articles published in JBB.

JBB is published monthly (2 vols. in 12 issues) by the Society for Biotechnology, Japan and distributed outside Japan by Elsevier. Online version is available in ScienceDirect. The journal was first published in 1923, originally being named Jyozogaku Zasshi (in Japanese) and then renamed Hakkokogaku Zasshi (in Japanese) (1944), Journal of Fermentation Technology (1973), and Journal of Fermentation and Bioengineering (1989). It was given the current name in 1999. JBB has established itself as one of the most influential biotechnology journals and is now highly appreciated by scientists throughout the world.

JBB is abstracted/indexed in BIOSIS, Chemical Abstracts, Current Contents, EMBASE/Excerpta Medica, Elsevier BIOBASE/Current Awareness in Biological Sciences, ISI Biotechnology Citation Index, and MEDLINE/PubMed.

Print ISSN 1389-1723
Online ISSN 1347-4421
CODEN: JBBIF6
Impact Factor: 1.707 (2010)
Eigenfactor Score: 38/160 in Biotechnology & Applied microbiology

Vol. 113 Cover Illustration

Reporter gene lac-z expression using adenoviral vector AdβGal in experimental liver fibrosis. Slide showing the expression of β-galactosidase in a liver section from a CCl4 chronically intoxicated rat during eight weeks.  Liver samples were cut utilizing a cryostat system 72 h after systemic administration of 2 x 10e11 total IU of AdβGal.  Analysis of protein expression was performed using X-gal reagent and counterstaining with neutral red. Blue cells show the expression of β-galactosidase protein from AdβGal vector indicating that therapeutic genes can be useful to remove liver fibrosis. This photograph was taken in the Institute of Molecular Medicine and Gene Therapy from the University of Guadalajara, Guadalajara, Jalisco, Mexico.

For more information regarding this work, read the article: Armendariz-Borunda, J. et al., "Production of first generation adenoviral vectors for preclinical protocols: Amplification, purification and functional titration", J. Biosci. Bioeng., volume 112, issue 5, pages 415-421 (2011).

►Back to JBB Top